Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. - Trial NCT06383780
Access comprehensive clinical trial information for NCT06383780 through Pure Global AI's free database. This Phase 3 trial is sponsored by XIANG YANQUN and is currently Recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
XIANG YANQUN
Sun Yat-sen University
Timeline & Enrollment
Phase 3
May 01, 2024
May 01, 2027
Primary Outcome
1-year progression-free survival rate
Summary
This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety
 of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab
 versus the TPC（cisplatin, nab-paclitaxel and capecitabine）regimen in combination with
 Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone
 Metastasis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06383780
Non-Device Trial